Nature Communications (Jun 2019)
Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen
- Michael P. Menden,
- Dennis Wang,
- Mike J. Mason,
- Bence Szalai,
- Krishna C. Bulusu,
- Yuanfang Guan,
- Thomas Yu,
- Jaewoo Kang,
- Minji Jeon,
- Russ Wolfinger,
- Tin Nguyen,
- Mikhail Zaslavskiy,
- AstraZeneca-Sanger Drug Combination DREAM Consortium,
- In Sock Jang,
- Zara Ghazoui,
- Mehmet Eren Ahsen,
- Robert Vogel,
- Elias Chaibub Neto,
- Thea Norman,
- Eric K. Y. Tang,
- Mathew J. Garnett,
- Giovanni Y. Di Veroli,
- Stephen Fawell,
- Gustavo Stolovitzky,
- Justin Guinney,
- Jonathan R. Dry,
- Julio Saez-Rodriguez
Affiliations
- Michael P. Menden
- Oncology, IMED Biotech Unit, AstraZeneca
- Dennis Wang
- Oncology, IMED Biotech Unit, AstraZeneca
- Mike J. Mason
- Sage Bionetworks
- Bence Szalai
- Department of Physiology, Faculty of Medicine, Semmelweis University
- Krishna C. Bulusu
- Oncology, IMED Biotech Unit, AstraZeneca
- Yuanfang Guan
- Department of Computational Medicine and Bioinformatics, University of Michigan
- Thomas Yu
- Sage Bionetworks
- Jaewoo Kang
- Department of Computer Science and Engineering, Korea University
- Minji Jeon
- Department of Computer Science and Engineering, Korea University
- Russ Wolfinger
- SAS Institute, Inc
- Tin Nguyen
- Department of Computer Science and Engineering, University of Nevada
- Mikhail Zaslavskiy
- Independent Consultant in Computational Biology, Owkin, Inc.
- AstraZeneca-Sanger Drug Combination DREAM Consortium
- In Sock Jang
- Sage Bionetworks
- Zara Ghazoui
- Oncology, IMED Biotech Unit, AstraZeneca
- Mehmet Eren Ahsen
- IBM Thomas J. Watson Research Center, Yorktown Heights
- Robert Vogel
- IBM Thomas J. Watson Research Center, Yorktown Heights
- Elias Chaibub Neto
- Sage Bionetworks
- Thea Norman
- Sage Bionetworks
- Eric K. Y. Tang
- Oncology, IMED Biotech Unit, AstraZeneca
- Mathew J. Garnett
- Wellcome Trust Sanger Institute
- Giovanni Y. Di Veroli
- Early Clinical Development, IMED Biotech Unit, AstraZeneca
- Stephen Fawell
- Oncology, IMED Biotech Unit, AstraZeneca, R&D Boston
- Gustavo Stolovitzky
- IBM Thomas J. Watson Research Center, Yorktown Heights
- Justin Guinney
- Sage Bionetworks
- Jonathan R. Dry
- Oncology, IMED Biotech Unit, AstraZeneca, R&D Boston
- Julio Saez-Rodriguez
- European Bioinformatics Institute, European Molecular Biology Laboratory
- DOI
- https://doi.org/10.1038/s41467-019-09799-2
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 17
Abstract
Resistance to first line treatment is a major hurdle in cancer treatment, that can be overcome with drug combinations. Here, the authors provide a large drug combination screen across cancer cell lines to benchmark crowdsourced methods and to computationally predict drug synergies.
